Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GORDON B MILLS and FUNDA MERIC-BERNSTAM.
GORDON B MILLS
Connection Strength
11.003
FUNDA MERIC-BERNSTAM
  1. Reply to M.P. Decatris et al. J Clin Oncol. 2016 Mar 10; 34(8):886.
    View in: PubMed
    Score: 0.542
  2. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
    View in: PubMed
    Score: 0.518
  3. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
    View in: PubMed
    Score: 0.514
  4. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83.
    View in: PubMed
    Score: 0.484
  5. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol. 2013 May 20; 31(15):1849-57.
    View in: PubMed
    Score: 0.448
  6. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol. 2012 Sep; 9(9):542-8.
    View in: PubMed
    Score: 0.426
  7. Quantitative proteomic analysis in breast cancer. Drugs Today (Barc). 2011 Feb; 47(2):169-82.
    View in: PubMed
    Score: 0.384
  8. Mammalian target of rapamycin. Semin Oncol. 2004 Dec; 31(6 Suppl 16):10-7; discussion 33.
    View in: PubMed
    Score: 0.251
  9. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol. 2024 Jul 31; 8(1):166.
    View in: PubMed
    Score: 0.245
  10. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep. 2023 11 18; 13(1):20223.
    View in: PubMed
    Score: 0.233
  11. Actionability classification of variants of unknown significance correlates with functional effect. NPJ Precis Oncol. 2023 Jul 15; 7(1):67.
    View in: PubMed
    Score: 0.228
  12. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res. 2021 06 01; 27(11):3243-3252.
    View in: PubMed
    Score: 0.194
  13. Prospecting whole cancer genomes. Nat Cancer. 2020 03; 1(3):273-275.
    View in: PubMed
    Score: 0.180
  14. Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2019 Aug 27; 10(50):5254.
    View in: PubMed
    Score: 0.174
  15. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
    View in: PubMed
    Score: 0.172
  16. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.170
  17. Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer. 2018; 4:34.
    View in: PubMed
    Score: 0.164
  18. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.159
  19. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell. 2018 03 12; 33(3):401-416.e8.
    View in: PubMed
    Score: 0.157
  20. Physician interpretation of genomic test results and treatment selection. Cancer. 2018 03 01; 124(5):966-972.
    View in: PubMed
    Score: 0.154
  21. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477.
    View in: PubMed
    Score: 0.153
  22. Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes. JCO Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.153
  23. Clinical Use of Precision Oncology Decision Support. JCO Precis Oncol. 2017; 2017.
    View in: PubMed
    Score: 0.152
  24. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2017 Jun 27; 8(26):41806-41814.
    View in: PubMed
    Score: 0.150
  25. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016 Nov 22; 7(47):76362-76373.
    View in: PubMed
    Score: 0.144
  26. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404.
    View in: PubMed
    Score: 0.139
  27. High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clin Cancer Res. 2016 Oct 15; 22(20):5068-5078.
    View in: PubMed
    Score: 0.139
  28. Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2016; 11(3):e0151121.
    View in: PubMed
    Score: 0.137
  29. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol. 2016 05; 27(5):795-800.
    View in: PubMed
    Score: 0.136
  30. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
    View in: PubMed
    Score: 0.134
  31. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
    View in: PubMed
    Score: 0.132
  32. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
    View in: PubMed
    Score: 0.132
  33. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov Today. 2015 Dec; 20(12):1433-8.
    View in: PubMed
    Score: 0.131
  34. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
    View in: PubMed
    Score: 0.127
  35. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57.
    View in: PubMed
    Score: 0.124
  36. Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. Cancer Cell. 2014 Jul 14; 26(1):7-9.
    View in: PubMed
    Score: 0.122
  37. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
    View in: PubMed
    Score: 0.119
  38. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther. 2014 May; 13(5):1382-9.
    View in: PubMed
    Score: 0.119
  39. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov Med. 2014 Feb; 17(92):101-14.
    View in: PubMed
    Score: 0.118
  40. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat. 2013 Jan; 137(1):319-27.
    View in: PubMed
    Score: 0.109
  41. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol. 2013 Apr; 24(4):909-16.
    View in: PubMed
    Score: 0.109
  42. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res. 2012 Oct 26; 14(5):R138.
    View in: PubMed
    Score: 0.108
  43. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012 Oct 15; 18(20):5816-28.
    View in: PubMed
    Score: 0.107
  44. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
    View in: PubMed
    Score: 0.104
  45. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics. 2011 Jul 08; 8(1):11.
    View in: PubMed
    Score: 0.099
  46. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011 Jun; 10(6):1093-101.
    View in: PubMed
    Score: 0.097
  47. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.
    View in: PubMed
    Score: 0.096
  48. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics. 2010 Dec; 6(4):129-51.
    View in: PubMed
    Score: 0.095
  49. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther. 2010 Oct; 9(10):2770-84.
    View in: PubMed
    Score: 0.094
  50. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res. 2005 Mar 01; 65(5):1961-72.
    View in: PubMed
    Score: 0.064
  51. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004 Oct 15; 10(20):7031-42.
    View in: PubMed
    Score: 0.062
  52. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res. 2004 Feb 01; 10(3):1013-23.
    View in: PubMed
    Score: 0.059
  53. Molecular therapeutics: promise and challenges. Semin Oncol. 2004 Feb; 31(1 Suppl 3):39-53.
    View in: PubMed
    Score: 0.059
  54. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res. 2022 Apr 20.
    View in: PubMed
    Score: 0.052
  55. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep. 2022 Apr; 40:100974.
    View in: PubMed
    Score: 0.052
  56. A functional genomic approach to actionable gene fusions for precision oncology. Sci Adv. 2022 02 11; 8(6):eabm2382.
    View in: PubMed
    Score: 0.052
  57. Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosin-Stained Sections of Core-Needle Biopsy Specimens. JAMA Netw Open. 2020 03 02; 3(3):e200476.
    View in: PubMed
    Score: 0.045
  58. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020 07 15; 147(2):413-422.
    View in: PubMed
    Score: 0.044
  59. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. Eur J Cancer. 2019 10; 120:54-64.
    View in: PubMed
    Score: 0.044
  60. Integrated transcriptomic-genomic tool Texomer profiles cancer tissues. Nat Methods. 2019 05; 16(5):401-404.
    View in: PubMed
    Score: 0.042
  61. Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 05; 18(5):991-1000.
    View in: PubMed
    Score: 0.042
  62. Cancer driver mutation prediction through Bayesian integration of multi-omic data. PLoS One. 2018; 13(5):e0196939.
    View in: PubMed
    Score: 0.040
  63. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018 03 12; 33(3):450-462.e10.
    View in: PubMed
    Score: 0.039
  64. Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res. 2018 06 15; 24(12):2719-2731.
    View in: PubMed
    Score: 0.039
  65. "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. Cancer Res. 2017 11 01; 77(21):e123-e126.
    View in: PubMed
    Score: 0.038
  66. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
    View in: PubMed
    Score: 0.037
  67. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud. 2017 Jan; 3(1):a001115.
    View in: PubMed
    Score: 0.036
  68. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
    View in: PubMed
    Score: 0.036
  69. Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. BMC Genomics. 2016 06 23; 17 Suppl 2:394.
    View in: PubMed
    Score: 0.035
  70. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol. 2016 06; 27(6):1068-1074.
    View in: PubMed
    Score: 0.034
  71. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1699-712.
    View in: PubMed
    Score: 0.033
  72. TransVar: a multilevel variant annotator for precision genomics. Nat Methods. 2015 Nov; 12(11):1002-3.
    View in: PubMed
    Score: 0.033
  73. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14.
    View in: PubMed
    Score: 0.032
  74. Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2015 Jan 28; 6:4852.
    View in: PubMed
    Score: 0.032
  75. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53.
    View in: PubMed
    Score: 0.032
  76. RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab. 2015 Mar; 100(3):788-93.
    View in: PubMed
    Score: 0.032
  77. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
    View in: PubMed
    Score: 0.031
  78. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 2014 Oct 15; 5(19):9049-64.
    View in: PubMed
    Score: 0.031
  79. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.031
  80. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent?) a VEGFR2/PDGFR?/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol. 2014 Aug 01; 7:52.
    View in: PubMed
    Score: 0.031
  81. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014 May 29; 5:3887.
    View in: PubMed
    Score: 0.030
  82. Bias from removing read duplication in ultra-deep sequencing experiments. Bioinformatics. 2014 04 15; 30(8):1073-1080.
    View in: PubMed
    Score: 0.029
  83. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2014 Feb; 23(2):316-23.
    View in: PubMed
    Score: 0.029
  84. CanDrA: cancer-specific driver missense mutation annotation with optimized features. PLoS One. 2013; 8(10):e77945.
    View in: PubMed
    Score: 0.029
  85. Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol. 2013 Oct; 24(10):2522-2526.
    View in: PubMed
    Score: 0.029
  86. The impact of tumor heterogeneity on patient treatment decisions. Clin Chem. 2013 Jan; 59(1):38-40.
    View in: PubMed
    Score: 0.027
  87. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15.
    View in: PubMed
    Score: 0.026
  88. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77.
    View in: PubMed
    Score: 0.026
  89. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res. 2012 Feb 15; 18(4):1109-19.
    View in: PubMed
    Score: 0.026
  90. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer. 2010 Nov; 10 Suppl 3:S59-65.
    View in: PubMed
    Score: 0.024
  91. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009 May; 8(5):1157-68.
    View in: PubMed
    Score: 0.021
  92. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell. 2009 Apr 07; 15(4):304-14.
    View in: PubMed
    Score: 0.021
  93. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009 Apr 01; 15(7):2472-8.
    View in: PubMed
    Score: 0.021
  94. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell. 2006 Aug; 10(2):145-57.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.